Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
AssigneeSignal Pharmaceuticals, LLC
InventorsYoshitaka Satoh, Shripad S. Bhagwat
Life of this patent
Estimating the term…
Abstract
This invention generally relates to methods for treating or preventing a condition responsive to JNK inhibition, such as a metabolic condition, comprising administering to a patient in need thereof an effective amount of an Anilinopyrimidine Derivative having the following structure: 1 or a pharmaceutically acceptable salt thereof, wherein R1 through R6 are as defined herein.
Claims7
A method for treating or preventing a metabolic condition, comprising administering to a patient in need thereof an effective amount of a compound having the structure:
- 544
- or a pharmaceutically acceptable salt thereof,
- wherein:
- R1 is aryl or heteroaryl optionally substituted with one to four substituents independently selected from R7;
- R2 and R3 are the same or different and are independently hydrogen or lower alkyl;
- R4 represents one to four optional substituents, wherein each substituent is the same or different and independently selected from halogen, hydroxy, lower alkyl or lower alkoxy;
- R5 and R6 are the same or different and independently —R8, —(CH2)αC(═O)R9, —(CH2)αC(═O)OR9, —(CH2)αC(═O)NR9R10, —(CH2)αC(═O)NR9(CH2)bC(═O)R10, —(CH2)αNR9C(═O)R10, —(CH2)αNR11C(═O)NR9R10, —(CH2)αNR9R10, —(CH2)αOR9, —(CH2)αSOcR9, or —(CH2)αSO2NR9R10;
- or R5 and R6 taken together with the nitrogen atom to which they are attached to form a heterocycle or substituted heterocycle:
- R7 is at each occurrence independently halogen, hydroxy, cyano, nitro, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, Sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, —C(═O)OR8, —OC(═O)R8, —C(═O)NR8R9, —C(═O)NR8OR9, —SOcR8, —SOcNR8R9, —NR8SOcR9, —NR8R9, —NR8C(═O)R9, —NR8C(O)(CH2)bOR9, —NR8C(═O)(CH2)bR9, —O(CH2)bNR8R9, or heterocycle fused to phenyl;
- R8, R9, R10 and R11 are the same or different and at each occurrence independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl;
- or R8 and R9 taken together with the atom or atoms to which they are attached to form a heterocycle or substituted heterocycle;
- a and b are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;
- and
- c is at each occurrence 0, 1 or 2.
A method for treating or preventing otitis externa, acute otitis media, hearing loss, pulmonary interstitial fibrosis, liver fibrosis, renal fibrosis, wound-healing, burn-healing, chronic obstructive pulmonary disease, allergy, allergic rhinitis, acute respiratory distress syndrome, systemic lupus erythematosus, nephropathy, pancreatitis, peritonitis, sepsis, alcohol or toxin-induced liver disease, sclerosis, steatosis or ischemia-reperfusion injury, comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound having the structure:
- 545
- or a pharmaceutically acceptable salt thereof,
- wherein:
- R1 is aryl or heteroaryl optionally substituted with one to four substituents independently selected from R7;
- R2 and R3 are the same or different and are independently hydrogen or lower alkyl;
- R4 represents one to four optional substituents, wherein each substituent is the same or different and independently selected from halogen, hydroxy, lower alkyl or lower alkoxy;
- R5 and R6 are the same or different and independently —R8, —(CH2)αC(═O)R9, —(CH2)αC(═O)OR9 , —(CH2)αC(═O)NR9R10, —(CH2)αC(═O)NR9(CH2)bC(═O)R10, —(CH2)αNR9C(═O)R10, —(CH2)αNR11C(═O)NR9R10, —(CH2)αNR9R10, —(CH2)αOR9, —(CH2)αSOcR9, or —(CH2)αSO2NR9R10;
- or R5 and R6 taken together with the nitrogen atom to which they are attached to form a heterocycle or substituted heterocycle;
- R7 is at each occurrence independently halogen, hydroxy, cyano, nitro, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylakyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, —C(═O)OR8, —OC(═O)R8, —C(═O)NR8R9, —C(═O)NR8OR9, —SOcR8, —SOcNR8R9, —NR8SOcR9, —NR8R9, —NR8C(═O)R9 ,—NR8C(═O)(CH2)bOR9, —NR8C(═O)(CH2)bR9, —O(CH2)bNR8R9, or heterocycle fused to phenyl;
- R8, R9, R10 and R11 are the same or different and at each occurrence independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl;
- or R8 and R9 taken together with the atom or atoms to which they are attached to form a heterocycle or substituted heterocycle;
- a and b are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;
- and
- c is at each occurrence 0, 1 or 2.
A method for treating or preventing a disease responsive to JNK inhibition, comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound having the structure:
- 546
- or a pharmaceutically acceptable salt thereof,
- wherein:
- R1 is aryl or heteroaryl optionally substituted with one to four substituents independently selected from R7;
- R2 and R3 are the same or different and are independently hydrogen or lower alkyl;
- R4 represents one to four optional substituents, wherein each substituent is the same or different and independently selected from halogen, hydroxy, lower alkyl or lower alkoxy;
- R5 and R6 are the same or different and independently —R8, —(CH2)αC(═O)R9, —(CH2)αC(═O)OR9, —(CH2)αC(═O)NR9R10, —(CH2)αC(═O)NR9(CH2)bC(═O)R10, —(CH2)αNR9C(═O)R10, —(CH2)αNR11C(═O)NR9R10, —(CH2)αNR9R10, —(CH2)αOR9, —(CH2)αSOcR9, or —(CH2)αSO2NR9R10;
- or R5 and R6 taken together with the nitrogen atom to which they are attached to form a heterocycle or substituted heterocycle;
- R7 is at each occurrence independently halogen, hydroxy, cyano, nitro, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylakyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, —C(═O)OR8, —OC(═O)R8, —C(═O)NR8R9, —C(═O)NR8OR9, —SOcR8, —SOcNR8R9, —NR8SOcR9, —NR8R9, —NR8C(═O)R9, —NR8C(═O)(CH2)bOR9, —NR8C(═O)(CH2)bR9, —O(CH2)bNR8R9, or heterocycle fuised to phenyl;
- R8, R9, R10 and R11 are the same or different and at each occurrence independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl or substituted heterocyclealkyl;
- or R8 and R9 taken together with the atom or atoms to which they are attached to form a heterocycle or substituted heterocycle;
- a and b are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;
- and
- c is at each occurrence 0, 1 or 2.
Dependencies are inferred from the claim text.